newsfilter
← Latest News
GlobeNewswire·

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced melanoma